DOCSLIB.ORG

Poster Authors: Martin Lee Miller, Søren Brunak, Lars Juhl Jensen, Michael B

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Poster Authors: Martin Lee Miller, Søren Brunak, Lars Juhl Jensen, Michael B A Sequence-Specificity Atlas of the Kinase World CK1 family NEK2 Negative Atypical S TGFbR2 S D F T EIF2AK2 YS SY A EE S F EDDETDG S DTTYGA 0 1 2 3 4 5 6 7 -7 -6 -5 -4 -3 -2 -1 L I M S TR FWMW VS W G LT Y H T 0 1 2 3 4 5 6 7 -7 -6 -5 -4 -3 -2 -1 E S R CK1gamma3 CK1gamma1 CK1gamma2 R K T TS DE CK1epsilon S CK1alpha2 NND QRN S KKS M CQ CK1alpha 0 1 2 3 4 5 6 7 O -6 -5 -4 -3 -2 -1 T CK1delta -7 V D KRT R D E RL D R SEL T PTTS LD T S S L S SK LM PLP LS E E P A E K RG LDLF Y G V N G GR L I A T LV VAY TT TTBK2 KR I T RVFS I RE KA TDD RS KQ KM D EE G G BUBR1 TTBK1 VRK2 VRK1 N RE P D SgK396 VRK3 MPKRT F NFNMGPM SgK196 P I GMVHG KYL I MEL SgK493 Positive 0 SgK110 Haspin S BUB1 -7 -6 -5 -4 -3 -2 -1 SgK069 +3 +4 +5 +6 +7 +1 +2 SgK223 SgK269 Wnk2 Wnk4 Wnk3 NRBP1 ATM/ATR NRBP2 Wnk1 SCYL2 SCYL1 SCYL3 PIK3R4 Slob SgK424 SgK307 PINK1 SBK SgK496 MOS TBCK PBK CYGF CDC7 CYGD HSER NEK1 ANPb Proline NEK5 ANPa ILK NEK3 BMPR2 NEK11NEK4 MISR2 TGFbR2 ACTR2 NEK2 ACTR2B ALK2 NEK9 ALK1 NEK8 BMPR1B NEK6 BMPR1A NEK10NEK7 ALK7 TGFbR1 ALK4 AAK1 MLKL IRAK4 S S MPSK1 BIKE IRAK2 E Q EIF2AK2 S D G S E IRAK1 ES A S PS I SS GAK TQL PL SQ DL Syk family S VP Tec family P D E IRAK3 EphB3 L T GCN2 1 TESK2 0 PEK TESK1 -7 -6 -5 -4 -3 -2 -1 S +1 +2 +3 +4 +5 +6 +7 Q LIMK1 Wee1B LIMK2 mTOR LRRK2 HRI LRRK1 Wee1 RIPK1 MYT1 RIPK3 RNAseL RIPK2 IRE1 ANKRD3 IRE2 SgK288 KSR2 SgK071 KSR1 D E V L P KIS ARAF EV P S D R TTK E D D R VE AD VS A EE D DG V SSDDE EY NP R BRAF D V L E M ATPVD CLIK1LCLIK1 S EES E YE L LEE QLT EN PD E A L D T I SP NQ DG ANSS D DEE S DLL MS G PS P K A SD TEN T NGLKND D RAF1 LMP N MN P KS DV E E T A TM ED R D PP NQP ESEQ P N A S S TSE R D H Q T I GH F M L S P VT TT S HH498 E V 0 SS T G P PRPK 0 S 0 1 2 3 4 5 6 7 E R G S P -7 -6 -5 -4 -3 -2 -1 RQP SS L -7 -6 -5 -4 -3 -2 -1 -7 -6 -5 -4 -3 -2 -1 MAP3K7 2 +1 +2 +3 +4 +5 +6 +7 +7 S RA AlphaK1 +1 +2 +3 +4 +5 +6 F I FL N S DG PVVTCPV R PL V TTDF Q D VFT ZAK GRQRG D R GD AlphaK2 PM K YPAFP DNEGP I F E I F NLKLVTK ET I KL DLK Y Y FGGHYGH F I KKGV I Y MAP3K13 0 P eEF2K -7 -6 -5 -4 -3 -2 -1 T +4 +5 +6 +7 +1 +2 +3 MAP3K10 Chak1 MLK4 DNAPK AlphaK3Chak2 MAP3K9 EphA4 Abl family MAP3K11 ATR FAK mTORATM PYK2 TRRAP Syk ZAP70 DNAPKSMG1 EphA10 PDHK3 CK1 EphB6 E PDHK1 EphA1 T S SS AP AT D Q BCKDK EphA2 P Q ET L QS L E V LF I D S S FP T L EE S AS PD EphA8 V LF V G G D I G D Q Q AE SK R P G G AHQ PDHK4 V V T E V SVGP DV AP D L S V Q I MGG L G I NG A P R K D E G TTK VT N N SN F A R EP A H NQ GM E EphB4 Y YY DG VG LS S TE LF T Q I K G V S P VP I T LQG T PDHK2 C YNFH P A P Q C 0 T EphB3 0 0 1 2 3 4 5 6 7 -7 -6 -5 -4 -3 -2 -1 -7 -6 -5 -4 -3 -2 -1 -7 -6 -5 -4 -3 -2 -1 +1 +2 +3 +4 +5 +6 +7 ADCK1 EphB1 +1 +2 +3 +4 +5 +6 +7 ADCK5 EphB2 Y ADCK3 EphA7 ADCK4 EphA6 ADCK2 EphA4 EphA3 PDGFRY family Lck Brd3 EphA5 TIF1gammaBrd2 CTK Brd4 Csk TIF1alphaBrdT Fer Fes CaMKIIβ TIF1beta Abl2 Abl RIOK1 BMX V V RIOK3 EEE I I L PIKK BTK DDE I V QG I D SSSD FDF T A V PPPS Y E EE E NN TTP MEM D DEF RIOK2 EEST T YP DGGLE G T E L N YW NEK ITK PP Y L Y 0 1 2 3 4 5 6 7 0 1 2 3 4 5 6 7 -7 -6 -5 -4 -3 -2 -1 Tec -7 -6 -5 -4 -3 -2 -1 S TXK Srm FD Brk M I K K Q VS I F I F FRQL M M Y MK LELK FRK W SY RKN YTTW CaMKIdelta FLT3/CSF1R/Kit 0 1 2 3 4 5 6 7 Y BLK Y -7 -6 -5 -4 -3 -2 -1 T CaMKIalpha CaMKIgamma Lck HCK CaMKIbeta Lyn CaMKIIα/δ Fgr CaMKIV Fyn VACAMKL Src S DY NL E PSKH2 Yes D N E DP S E RES VI YKR S N NAR E EG S KV GETQ Tie1 V I NV A I S A V TY G DT TDDLS PSKH1 D DN D SR AF P F G TAHF ERWQ N VKL D FTL K DCAMKL1 LNSS QK EFPPK F Tie2 I HMLFR I FLMHH G 0 DCAMKL2 -7 -6 -5 -4 -3 -2 -1 +1 +2 PDGFRalpha +3 +4 +5 +6 +7 T A L SQ LDT S RR A F Q DCAMKL3 PDGFRbeta S FLPRD V S G Y CaMKIIgamma SE KQ I TKL D REK R R SVAK TEE Atypical R AQQP R LL SY I S LP D S R G K FLT3 K M H S P K I HY T I I EK 0 CaMKIIbeta -7 -6 -5 -4 -3 -2 -1 CSF1R +1 +2 +3 +4 +5 +6 +7 CaMKIIalpha Kit CaMKIIdelta FLT4 JAK2/JAK3 MAPKAPK family KDR CASK Src FLT1 PHKg1 Ret PHKg2 FGFR4 RSK3 2 FGFR1 RSK2 2 FGFR3 P L P RSK1 2 FGFR2 DL TSD L SD SSLADK YK VPSG A A AV DE T SL VP L I L TV I S S RSK4 2 CCK4 PHSSQA I PTKFTD L Q P A R E R H V E HA P L H I G P T TEE FD P VW P L R T PPT T S E LS I EQ SE K NLR P P SSA GG TP G MEKD SS P V A A I KK YG E I F I K GA RK V SE TP FSAA TDQKSP MSK2 2 Lmr3 RRGPDGE R L VE L V MRVET T E GT T R R QT P G 0 V NP DGG N N DE I L K LL FG E -7 -6 -5 -4 -3 -2 -1 +7 T MSK1 2 Lmr1 +1 +2 +3 +4 +5 +6 0 -7 -6 -5 -4 -3 -2 -1 S +1 +2 +3 +4 +5 +6 +7 Lmr2 Y Mnk2 Mnk1 SuRTK106 PKD family MAPKAPK2 Tyk2 2 MAPKAPK3 JAK1 2 EGFR MAPKAPK5 JAK2 2 JAK3 2 PKD3 TK TNK2 PKD1 TNK1 S PKD2 Tyk2 CHK2 JAK1 LV V F MARK2 E F F K MM JAK3 I YA LKKK VF F DPE V A RQ L M E L P A EM FA V EDI LP V I I DND V I L MARK1 V F I V I Y P Y S H H YP N SS W WWW JAK2 NPST TYY TMM GWY I M TTT RC MMY G P T W 0 1 2 3 4 5 6 7 MARK3 0 1 2 3 4 5 6 7 -7 -6 -5 -4 -3 -2 -1 ErbB3 MARK4 ErbB4 -7 -6 -5 -4 -3 -2 -1 SIK ErbB2 CHK2 QIK EGFR Met family QSK RYK Y NuaK1 Ron NuaK2 CAMK Met BRSK2 Sky BRSK1 Axl S Mer AMPKa1 Ros V L AMPKa2 DEE V T AD PPPPA T I Q I SVHLGDN D G M S ALK YD VR T I NTS R Y R I S A SMT TY T E A S Y N F S FR MELK M L QV N DQ S MN L GAE S CV Y A VR L Y TE H D RC K M A MC F ERC L H C S KSP L L L W HK WW RM D MFEKN P Y H LTK PQTPKM K H R HUNK HS N I L THNGY V 0 1 2 3 4 5 6 7 STE 0 -7 -6 -5 -4 -3 -2 -1 R T -7 -6 -5 -4 -3 -2 -1 IRR +2 +3 +4 +5 +6 +7 CHK1 +1 LKB1 InsR Y SSTK IGF1R AMPK subfamily DDR2 TSSK3 DDR1 InsR/IGF1R TSSK1 ROR1 TSSK2 ROR2 TSSK4 Musk NIM1 TRKA S SNRK TRKB Pim1 M Pim3 TRKC L Pim2 R SLK D R H I R L E ND SP D G ME G S GE MS I NGK LE DPP ANPYSVK 0 1 2 3 4 5 6 7 PASK S KK E I A P R T G EG T V L -7 -6 -5 -4 -3 -2 -1 LOK T S Trb2 0 MAP4K1 -7 -6 -5 -4 -3 -2 -1 Trb1 MAP4K2 Y +1 +2 +3 +4 +5 +6 +7 LKB1 Trb3 KHS2 MAP4K5 SgK495 MYO3A SgK085 MYO3B caMLCK NRK skMLCK TNIK smMLCKTTN MAP4K6 MAP4K4 I DAPK1 TAO3 WF CMGC F YYLV PWTR T AGC CM DAPK3 S P TAO1 M A W C 0 1 2 3 4 5 6 7 DAPK2 TAO2 -7 -6 -5 -4 -3 -2 -1 PKC DRAK2 MAP3K MST1 T DRAK1 MST2 YSK1 TNIK SLK Pim1 Pim2 Obscn 2 SPEG 2 MST3 MST4 SPEG 1 PAK2 ObscnTrad 1 CDK Trio PAK1 PAK3 STK33 PAK6 S PAK4 S ULK1 PAK5 LRRR R R ULK2 R M OSR1 P YG K H W Y WN MKP RH H G W Q K Y LKR G H H Y H H S N K N H R R RN P WI NS HKK Y K D Q NHK R ULK3 T T C T KF FG H R N Q STLK3 S S CTST R QT I T N Y RN W K NW R K R N P KK K KK G H RQ SRHY WR W AKQ 0 1 2 3 4 5 6 7 HQ S G ULK4 STLK5 0 1 2 3 4 5 6 7 -7 -6 -5 -4 -3 -2 -1 -7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 0 1 2 3 4 5 6 7 -7 -6 -5 -4 -3 -2 -1 -7 -6 -5 -4 -3 -2 -1 T T STLK6 Fused MAP2K5 MAPK MAP2K1 PKCbeta MAP2K2 PAK4 PAK2 PKCalpha MAP2K7 T MAP2K4 T MAP2K6 PKCgammaPKCeta MAP2K3 PKCepsilon MAP3K8 PKCtheta MAP3K14 PKCdelta GCN2 2 PKCzeta PKC family SGK family PKN1 MAP3K4 PKCiota MAP3K6 PKN2 MAP3K7 S PKN3 R W MAP3K5 I A RK C HH V LY SGK3 MYW W F SYR Y ST I K K R MAP3K1 Q SF S S W Y L SY P G FVL R V W SGK1 MAP3K8 2 RNHS C R 0 1 2 3 4 5 6 7 0 1 2 3 4 5 6 7 -7 -6 -5 -4 -3 -2 -1 T SGK2 -7 -6 -5 -4 -3 -2 -1 R MAP3K3 R S MAP3K2 T D PKBbeta CK2alpha S C A P S A S RSK1 CK2a2 G P S MAP2K3/4/6/7 MST1 AS S N S PKBalpha Polo MST4 P T V T G DR R LT ANPE CDK10 TQ A A M LVV S RSK2 S A S GSRE N R EF R V SDQ I N D W T PITSLRE RR LG LL AE RSK3 S RP K K K KSR N G N VQ L R G I L HG YRK I SS S KS L PKBgamma CDK9 T T RSK4 0 0 -7 -6 R-5 -4 -3 -2 -1 CRK7 -7 -6 -5 -4 -3 -2 -1 +2 +3 +4 +5 +6 +7 +1 +1 +2 +3 +4 +5 +6 +7 CHED R CDK7 RSK5 p70S6Kbp70S6K CDK11 CDK8 MSK2GRK5 1 CDK6 E A GRK4 CDK4 T Y A T M CDK5 S V V R GRK6 TSDDMTG V TWYR PKB family p70S6K subfamily RSK family GRK7 CDK1 MR SVT D PA R A E C P K CDK3 RDG LV GV T M C T GRK1 Y R AQ K W G DY W V LTE F MV Y D N CDK2 G L RFKVA Y AAPW WG R H DKD L N C K QKMS P R E S W K KSR GRK2 PFTAIRE1 A W G K L TWM GD A W K RR H E ND A M NR YQR TP M T RT M E STM HA NNH YKK G VG Q LES SL G H CI P A M P R CY RG I P L HY N GRK3 PFTAIRE2 Q G Q T VHSY I LT I MDSYK I M R S R PCTAIRE3 0 0 1 2 3 4 5 6 7 0 1 2 3 4 5 6 7 -7 -6 -5 -4 -3 -2 -1 -7 -6 -5 -4 -3 -2 -1 PCTAIRE1 -7 -6 -5 -4 -3 -2 -1 MRCKa PCTAIRE2 +1 +2 +3 +4 +5 +6 +7 MRCKb CCRK MAPK6 DMPK2 MAPK4 T DMPK1 MAPK15 ROCK2 NDR1 MAPK1 S ROCK1 MAPK3 NDR2CRIK MAPK7 NLK S MAPK9 F P LATS2 MAPK10 CK2 family T W RS MAPK8 T S E RSR S G R R R P LATS1 I K H SRG G V N S F Y R GS R SEK S MAPK13 P K S P A L G RDL LG WL DKA L ED MAPK12 S HN H C RRG WKM DP PF VN TKS Y N E LD EG S E K T M QRYS T LQSAK D P MAST4 MAPK14 Y KS R K H YLKQPT N I MAST1 MAPK11 CDKL5 0 1 2 3 4 5 6 7 0 1 2 3 4 5 6 7 0 MAST2 CDKL1 -7 -6 -5 -4 -3 -2 -1 -7 -6 -5 -4 -3 -2 -1 R T -7 -6 -5 -4 -3 -2 -1 S CDKL4 R +1 +2 +3 +4 +5 +6 +7 MAST3 CDKL2 CDKL3 MASTLYANK1 GSK3beta T GSK3alpha MOK R YANK2 ICK MAK YANK3 PRP4 SRPK1 SRPK2 MSSK1 RSKL2 CLK3 SgK494 CLK2 RSKL1 CLK1 CLK4 HIPK4 HIPK3 DYRK1B HIPK2 DYRK3 DYRK1A HIPK1 DYRK2 DYRK4 ROCK family PRKX DMPK family PKA family GRK subfamily PRKY PKAbeta PDK1 PLK2 PKAalpha PLK3 CDK2/CDK3 PLK1 PLK4 E TBK1 DE TLK1 TLK2 D ED EE PKAgamma E S DSD S S E E G S ESEEE G DDE S DD G GSSD AuroraB S T PKG2cGKIIPKG1cGKI AuroraC AuroraA ST IKKbeta 0 -4 -3 -2 -1 -7 -6 -5 IKKalpha +1 +2 +3 +4 +5 +6 +7 T IKKepsilon KR RR V CaMKKbeta S Y P S S R SR S CaMKKalpha RKSY G SS EM S I S VRMP D R DY T G S E GP RGVAR F S T GF T I YG S Q N QQ F T S S G K Q V D V G ASHL L GN S R ED D AV T GK R D D S PE CDK1 S E E T G V G AV NGEK FS P CDK4/CDK6 K T Q K Q A T D Q Q T K ER G D R KP F AS RS DE V S QS PAQTL I D L V T N E S P SE E TN LNVYVK K LL P P LG T K R T CLK family MAPK14 SR R 0 R P T 0 PLK1 AuroraA LR L G T S P L -7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 S S AR 0 S P LL -7 -6 -5 -4 -3 -2 -1 S TA +1 +2 +3 +4 +5 +6 +7 P H R -7 -6 -5 -4 -3 -2 -1 +1 +2 +3 +4 +5 +6 +7 G -7 -6 -5 -4 -3 -2 -1 LSS G Q P E H S +1 +2 +3 +4 +5 +6 +7 0 -7 -6 -5 -4 -3 -2 -1 T +1 +2 +4 +5 +6 +7 T P +3 PKGcGK family PDK1 JNK subfamily S S S S R S P R PAG RY PM P A VVAR R DA LS
Load more

Recommended publications
  • Supplementary Information Material and Methods
    MCT-11-0474 BKM120: a potent and specific pan-PI3K inhibitor Supplementary Information Material and methods Chemicals The EGFR inhibitor NVP-AEE788 (Novartis), the Jak inhibitor I (Merck Calbiochem, #420099) and anisomycin (Alomone labs, # A-520) were prepared as 50 mM stock solutions in 100% DMSO. Doxorubicin (Adriablastin, Pfizer), EGF (Sigma Ref: E9644), PDGF (Sigma, Ref: P4306) and IL-4 (Sigma, Ref: I-4269) stock solutions were prepared as recommended by the manufacturer. For in vivo administration: Temodal (20 mg Temozolomide capsules, Essex Chemie AG, Luzern) was dissolved in 4 mL KZI/glucose (20/80, vol/vol); Taxotere was bought as 40 mg/mL solution (Sanofi Aventis, France), and prepared in KZI/glucose. Antibodies The primary antibodies used were as follows: anti-S473P-Akt (#9271), anti-T308P-Akt (#9276,), anti-S9P-GSK3β (#9336), anti-T389P-p70S6K (#9205), anti-YP/TP-Erk1/2 (#9101), anti-YP/TP-p38 (#9215), anti-YP/TP-JNK1/2 (#9101), anti-Y751P-PDGFR (#3161), anti- p21Cip1/Waf1 (#2946), anti-p27Kip1 (#2552) and anti-Ser15-p53 (#9284) antibodies were from Cell Signaling Technologies; anti-Akt (#05-591), anti-T32P-FKHRL1 (#06-952) and anti- PDGFR (#06-495) antibodies were from Upstate; anti-IGF-1R (#SC-713) and anti-EGFR (#SC-03) antibodies were from Santa Cruz; anti-GSK3α/β (#44610), anti-Y641P-Stat6 (#611566), anti-S1981P-ATM (#200-301), anti-T2609 DNA-PKcs (#GTX24194) and anti- 1 MCT-11-0474 BKM120: a potent and specific pan-PI3K inhibitor Y1316P-IGF-1R were from Bio-Source International, Becton-Dickinson, Rockland, GenTex and internal production, respectively. The 4G10 antibody was from Millipore (#05-321MG).
    [Show full text]
  • Article Reference
    Article Phosphorylation by NLK inhibits YAP‐14‐3‐3‐interactions and induces its nuclear localization MOON, Sungho, et al. Reference MOON, Sungho, et al. Phosphorylation by NLK inhibits YAP‐14‐3‐3‐interactions and induces its nuclear localization. EMBO Reports, 2017, vol. 18, no. 1, p. 61-71 PMID : 27979972 DOI : 10.15252/embr.201642683 Available at: http://archive-ouverte.unige.ch/unige:112477 Disclaimer: layout of this document may differ from the published version. 1 / 1 Published online: December 15, 2016 Scientific Report Phosphorylation by NLK inhibits YAP-14-3-3- interactions and induces its nuclear localization Sungho Moon1,† , Wantae Kim1,†, Soyoung Kim1, Youngeun Kim1, Yonghee Song1, Oleksii Bilousov2, Jiyoung Kim1, Taebok Lee1, Boksik Cha1, Minseong Kim1, Hanjun Kim1, Vladimir L Katanaev2,3,* & Eek-hoon Jho1,** Abstract tissue homeostasis have become a long-standing topic of interest. As loss of the organ size control is linked to many human diseases, includ- Hippo signaling controls organ size by regulating cell proliferation ing cancer and degenerative diseases, regulation of the organ size and apoptosis. Yes-associated protein (YAP) is a key downstream could be an attractive therapeutic strategy. Recently, Hippo signaling effector of Hippo signaling, and LATS-mediated phosphorylation of has been identified as a major signaling pathway to control the organ YAP at Ser127 inhibits its nuclear localization and transcriptional size; dysregulation of this pathway results in aberrant growth [1]. activity. Here, we report that Nemo-like kinase (NLK) phosphory- The Hippo pathway is evolutionarily conserved from nematodes lates YAP at Ser128 both in vitro and in vivo, which blocks interac- to humans and controls a variety of cellular processes, such as cell tion with 14-3-3 and enhances its nuclear localization.
    [Show full text]
  • Table S1. Identified Proteins with Exclusive Expression in Cerebellum of Rats of Control, 10Mg F/L and 50Mg F/L Groups
    Table S1. Identified proteins with exclusive expression in cerebellum of rats of control, 10mg F/L and 50mg F/L groups. Accession PLGS Protein Name Group IDa Score Q3TXS7 26S proteasome non-ATPase regulatory subunit 1 435 Control Q9CQX8 28S ribosomal protein S36_ mitochondrial 197 Control P52760 2-iminobutanoate/2-iminopropanoate deaminase 315 Control Q60597 2-oxoglutarate dehydrogenase_ mitochondrial 67 Control P24815 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 84 Control Q99L13 3-hydroxyisobutyrate dehydrogenase_ mitochondrial 114 Control P61922 4-aminobutyrate aminotransferase_ mitochondrial 470 Control P10852 4F2 cell-surface antigen heavy chain 220 Control Q8K010 5-oxoprolinase 197 Control P47955 60S acidic ribosomal protein P1 190 Control P70266 6-phosphofructo-2-kinase/fructose-2_6-bisphosphatase 1 113 Control Q8QZT1 Acetyl-CoA acetyltransferase_ mitochondrial 402 Control Q9R0Y5 Adenylate kinase isoenzyme 1 623 Control Q80TS3 Adhesion G protein-coupled receptor L3 59 Control B7ZCC9 Adhesion G-protein coupled receptor G4 139 Control Q6P5E6 ADP-ribosylation factor-binding protein GGA2 45 Control E9Q394 A-kinase anchor protein 13 60 Control Q80Y20 Alkylated DNA repair protein alkB homolog 8 111 Control P07758 Alpha-1-antitrypsin 1-1 78 Control P22599 Alpha-1-antitrypsin 1-2 78 Control Q00896 Alpha-1-antitrypsin 1-3 78 Control Q00897 Alpha-1-antitrypsin 1-4 78 Control P57780 Alpha-actinin-4 58 Control Q9QYC0 Alpha-adducin 270 Control Q9DB05 Alpha-soluble NSF attachment protein 156 Control Q6PAM1 Alpha-taxilin 161
    [Show full text]
  • Androgen Receptor Modifications
    Kennedy’s Disease Research at the Lim Lab - Signaling pathway modulating Androgen Receptor post-translational modifications and its clearance as well as their contribution to KD Janghoo Lim, Ph.D. Department of Genetics Department of Neuroscience Program in Cellular Neuroscience, Neurodegeneration and Repair Yale University School of Medicine Translational Neuroscience Neurodegenerative Diseases successful therapies? gene identification SBMA pre-clinical trials disease models drug discovery pathogenesis studies candidate targets for therapeutic intervention Basic Neuroscience Translational Neuroscience Neurodegenerative Diseases successful therapies? gene identification SBMA pre-clinical trials disease models drug discovery pathogenesis studies candidate targets for therapeutic intervention Basic Neuroscience Translational Neuroscience Neurodegenerative Diseases successful therapies? gene identification SBMA pre-clinical trials disease models drug discovery pathogenesis studies candidate targets for therapeutic intervention Basic Neuroscience Translational Neuroscience Neurodegenerative Diseases successful therapies? gene identification SBMA pre-clinical trials disease models drug discovery pathogenesis studies candidate targets for therapeutic intervention Basic Neuroscience Are there any good candidate targets for therapeutic intervention for SBMA? Are there any good candidate targets for therapeutic intervention for SBMA? Nemo-Like Kinase (NLK) Nemo-Like Kinase (NLK) . Conserved MAPK-like serine/threonine protein kinase Cargnello et
    [Show full text]
  • Nemo-Like Kinase in Development and Diseases: Insights from Mouse Studies
    International Journal of Molecular Sciences Review Nemo-Like Kinase in Development and Diseases: Insights from Mouse Studies Renée Daams and Ramin Massoumi * Department of Laboratory Medicine, Translational Cancer Research, Faculty of Medicine, Lund University, 22381 Lund, Sweden; [email protected] * Correspondence: [email protected]; Tel.: +46-46-2226430 Received: 16 November 2020; Accepted: 1 December 2020; Published: 2 December 2020 Abstract: The Wnt signalling pathway is a central communication cascade between cells to orchestrate polarity and fate during development and adult tissue homeostasis in various organisms. This pathway can be regulated by different signalling molecules in several steps. One of the coordinators in this pathway is Nemo-like kinase (NLK), which is an atypical proline-directed serine/threonine mitogen-activated protein (MAP) kinase. Very recently, NLK was established as an essential regulator in different cellular processes and abnormal NLK expression was highlighted to affect the development and progression of various diseases. In this review, we focused on the recent discoveries by using NLK-deficient mice, which show a phenotype in the development and function of organs such as the lung, heart and skeleton. Furthermore, NLK could conduct the function and differentiation of cells from the immune system, in addition to regulating neurodegenerative diseases, such as Huntington’s disease and spinocerebellar ataxias. Overall, generations of NLK-deficient mice have taught us valuable lessons about the role of this kinase in certain diseases and development. Keywords: Nemo-like kinase (NLK); animal models; mice; development; immune system neuronal disorders 1. Introduction 1.1. Wnt Signalling Pathway The Wnt proteins consist of conserved, secreted glycoproteins harbouring essential roles in the mechanisms directing cell proliferation, cell polarity and cell fate determination during embryonic development, as well as adult tissue homeostasis in various organisms [1].
    [Show full text]
  • GPCR Signaling Inhibits Mtorc1 Via PKA Phosphorylation of Raptor
    RESEARCH ARTICLE GPCR signaling inhibits mTORC1 via PKA phosphorylation of Raptor Jenna L Jewell1,2,3*, Vivian Fu4,5, Audrey W Hong4,5, Fa-Xing Yu6, Delong Meng1,2,3, Chase H Melick1,2,3, Huanyu Wang1,2,3, Wai-Ling Macrina Lam4,5, Hai-Xin Yuan4,5, Susan S Taylor4,7, Kun-Liang Guan4,5* 1Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, United States; 2Harold C Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, United States; 3Hamon Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, United States; 4Department of Pharmacology, University of California, San Diego, La Jolla, United States; 5Moores Cancer Center, University of California San Diego, La Jolla, United States; 6Children’s Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai, China; 7Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, United States Abstract The mammalian target of rapamycin complex 1 (mTORC1) regulates cell growth, metabolism, and autophagy. Extensive research has focused on pathways that activate mTORC1 like growth factors and amino acids; however, much less is known about signaling cues that directly inhibit mTORC1 activity. Here, we report that G-protein coupled receptors (GPCRs) paired to Gas proteins increase cyclic adenosine 3’5’ monophosphate (cAMP) to activate protein kinase A (PKA) and inhibit mTORC1. Mechanistically, PKA phosphorylates the mTORC1 component Raptor on Ser 791, leading to decreased mTORC1 activity. Consistently, in cells where Raptor Ser 791 is mutated to Ala, mTORC1 activity is partially rescued even after PKA activation. Gas-coupled GPCRs *For correspondence: stimulation leads to inhibition of mTORC1 in multiple cell lines and mouse tissues.
    [Show full text]
  • Effect of Connective Tissue Growth Factor on Protein Kinase Expression and Activity in Human Corneal Fibroblasts
    Biochemistry and Molecular Biology Effect of Connective Tissue Growth Factor on Protein Kinase Expression and Activity in Human Corneal Fibroblasts Siva S. Radhakrishnan,1 Timothy D. Blalock,1,4 Paulette M. Robinson,1 Genevieve Secker,2 Julie Daniels,2 Gary R. Grotendorst,3 and Gregory S. Schultz1 PURPOSE. To investigate signal transduction pathways for CONCLUSIONS. Results from protein kinase screens and selective connective tissue growth factor (CTGF) in human corneal kinase inhibitors demonstrate Ras/MEK/ERK/STAT3 pathway is fibroblasts (HCF). required for CTGF signaling in HCF. (Invest Ophthalmol Vis Sci. 2012;53:8076–8085) DOI:10.1167/iovs.12-10790 METHODS. Expression of 75 kinases in cultures of serum-starved (HCF) were investigated using protein kinase screens, and changes in levels of phosphorylation of 31 different phospho- onnective tissue growth factor (CTGF) is a 38-kDa proteins were determined at 0, 5, and 15 minutes after Csecreted, cysteine-rich peptide that was first identified in treatment with CTGF. Levels of phosphorylation of three signal conditioned media from cultures of human umbilical vein transducing phosphoproteins (extracellular regulated kinase 1 endothelial cells (HUVEC).1,2 CTGF belongs to the CCN [ERK1], extracellular regulated kinase 2 [ERK2] [MAPKs], and [CTGF, Cyr61/Cef10, Nov] family of secreted cysteine-rich signal transducer and activator of transcription 3 [STAT3]) proteins, which possess growth regulatory functions and are were measured at nine time points after exposure to CTGF involved in cell differentiation.3–5 CTGF increases the produc- using Western immunoblots. Inhibition of Ras, MEK1/2 tion of components of the extracellular matrix such as (MAPKK), and ERK1/2, on CTGF-stimulated fibroblast prolif- collagen, integrin, and fibronectin.
    [Show full text]
  • Integrin-Linked Kinase Controls Renal Branching Morphogenesis Via Dual Specificity Phosphatase 8
    BASIC RESEARCH www.jasn.org Integrin-linked Kinase Controls Renal Branching Morphogenesis via Dual Specificity Phosphatase 8 †‡ Joanna Smeeton,* Priya Dhir,* Di Hu,* Meghan M. Feeney,* Lin Chen,* and † Norman D. Rosenblum* § *Program in Developmental and Stem Cell Biology, and §Division of Nephrology, The Hospital for Sick Children, Toronto, Ontario, Canada; and †Departments of Paediatrics, and ‡Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada ABSTRACT Integrin-linked kinase (ILK) is an intracellular scaffold protein with critical cell-specific functions in the embryonic and mature mammalian kidney. Previously, we demonstrated a requirement for Ilk during ureteric branching and cell cycle regulation in collecting duct cells in vivo. Although in vitro data indicate that ILK controls p38 mitogen-activated protein kinase (p38MAPK) activity, the contribution of ILK- p38MAPK signaling to branching morphogenesis in vivo is not defined. Here, we identified genes that are regulated by Ilk in ureteric cells using a whole-genome expression analysis of whole-kidney mRNA in mice with Ilk deficiency in the ureteric cell lineage. Six genes with expression in ureteric tip cells, including Wnt11, were downregulated, whereas the expression of dual-specificity phosphatase 8 (DUSP8) was upregulated. Phosphorylation of p38MAPK was decreased in kidney tissue with Ilk deficiency, but no significant decrease in the phosphorylation of other intracellular effectors previously shown to control renal morphogenesis was observed. Pharmacologic inhibition of p38MAPK activity in murine inner med- ullary collecting duct 3 (mIMCD3) cells decreased expression of Wnt11, Krt23,andSlo4c1.DUSP8over- expression in mIMCD3 cells significantly inhibited p38MAPK activation and the expression of Wnt11 and Slo4c1. Adenovirus-mediated overexpression of DUSP8 in cultured embryonic murine kidneys decreased ureteric branching and p38MAPK activation.
    [Show full text]
  • Nemo‑Like Kinase Expression Predicts Poor Survival in Colorectal Cancer
    MOLECULAR MEDICINE REPORTS 11: 1181-1187, 2015 Nemo‑like kinase expression predicts poor survival in colorectal cancer JINGBO CHEN1*, YUNWEI HAN2,3*, XIAOQIAN ZHAO4, MINGYU YANG1, BO LIU1, XIANGPENG XI1, XIAOLIN XU1, TIEJUN LIANG4 and LIJIAN XIA1 1Department of Gastrointestinal Surgery, Qianfoshan Hospital of Shandong Province; 2School of Medicine, Shandong University, Jinan, Shandong 250100; 3Department of Oncology, Affiliated Hospital of Luzhou Medical College, Luzhou, Sichuan 646000; 4Department of Digestive Diseases, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250014, P.R. China Received December 18, 2013; Accepted September 12, 2014 DOI: 10.3892/mmr.2014.2851 Abstract. Nemo-like kinase (NLK), a serine/threonine Introduction protein kinase, was previously reported to be associated with tumor proliferation and invasion. The present study aimed Colorectal cancer (CRC) is a prevalent type of cancer, to evaluate whether NLK participates in the tumorigenesis which has a high mortality rate worldwide (1). In Europe and progression of colorectal cancer (CRC). NLK expression and the USA, CRC is the third most common type of human was examined using reverse transcription quantitative poly- cancer and the second leading cause of cancer-associated merase chain reaction (RT-qPCR) and western blot analysis mortality (2,3). In China, the incidence of CRC has risen in 50 paired CRC tissues as well as immunohistochemical steadily over the last few decades, with increasing morbidi- analysis of 406 cases of primary CRC tissues and paired ties in younger patients (<50 years) (4). Recent cancer non-cancerous tissues. Correlations between NLK expression, statistics have indicated that CRC accounts for ~9% of all the clinicopathological features of CRC patients and clinical cancer-associated mortalities (5).
    [Show full text]
  • Inhibition of ERK 1/2 Kinases Prevents Tendon Matrix Breakdown Ulrich Blache1,2,3, Stefania L
    www.nature.com/scientificreports OPEN Inhibition of ERK 1/2 kinases prevents tendon matrix breakdown Ulrich Blache1,2,3, Stefania L. Wunderli1,2,3, Amro A. Hussien1,2, Tino Stauber1,2, Gabriel Flückiger1,2, Maja Bollhalder1,2, Barbara Niederöst1,2, Sandro F. Fucentese1 & Jess G. Snedeker1,2* Tendon extracellular matrix (ECM) mechanical unloading results in tissue degradation and breakdown, with niche-dependent cellular stress directing proteolytic degradation of tendon. Here, we show that the extracellular-signal regulated kinase (ERK) pathway is central in tendon degradation of load-deprived tissue explants. We show that ERK 1/2 are highly phosphorylated in mechanically unloaded tendon fascicles in a vascular niche-dependent manner. Pharmacological inhibition of ERK 1/2 abolishes the induction of ECM catabolic gene expression (MMPs) and fully prevents loss of mechanical properties. Moreover, ERK 1/2 inhibition in unloaded tendon fascicles suppresses features of pathological tissue remodeling such as collagen type 3 matrix switch and the induction of the pro-fbrotic cytokine interleukin 11. This work demonstrates ERK signaling as a central checkpoint to trigger tendon matrix degradation and remodeling using load-deprived tissue explants. Tendon is a musculoskeletal tissue that transmits muscle force to bone. To accomplish its biomechanical function, tendon tissues adopt a specialized extracellular matrix (ECM) structure1. Te load-bearing tendon compart- ment consists of highly aligned collagen-rich fascicles that are interspersed with tendon stromal cells. Tendon is a mechanosensitive tissue whereby physiological mechanical loading is vital for maintaining tendon archi- tecture and homeostasis2. Mechanical unloading of the tissue, for instance following tendon rupture or more localized micro trauma, leads to proteolytic breakdown of the tissue with severe deterioration of both structural and mechanical properties3–5.
    [Show full text]
  • Nlk Is a Murine Protein Kinase Related to Erk/MAP Kinases and Localized In
    Proc. Natl. Acad. Sci. USA Vol. 95, pp. 963–968, February 1998 Biochemistry Nlk is a murine protein kinase related to ErkyMAP kinases and localized in the nucleus BARBARA K. BROTT*, BENJAMIN A. PINSKY, AND RAYMOND L. ERIKSON Department of Molecular and Cellular Biology, Harvard University, 16 Divinity Avenue, Cambridge, MA 02138 Contributed by Raymond L. Erikson, December 5, 1997 ABSTRACT Extracellular-signal regulated kinasesy Cdks are crucial regulators that control transitions between microtubule-associated protein kinases (ErkyMAPKs) and the successive stages of the cell cycle. Activity of Cdks is tightly cyclin-directed kinases (Cdks) are key regulators of many controlled by various phosphorylation events and by the aspects of cell growth and division, as well as apoptosis. We association of cyclins, whose expression fluctuates throughout have cloned a kinase, Nlk, that is a murine homolog of the the cell cycle. At least eight members of the Cdk family have Drosophila nemo (nmo) gene. The Nlk amino acid sequence is been identified, with even more cyclins reported. The activity 54.5% similar and 41.7% identical to murine Erk-2, and 49.6% of Cdks is also negatively regulated by the association of small similar and 38.4% identical to human Cdc2. It possesses an inhibitory molecules (14, 15). Targets of Cdks include various extended amino-terminal domain that is very rich in glu- transcriptional coactivators such as p110Rb and p107, and tamine, alanine, proline, and histidine. This region bears transcription factors such as p53, E2F, and RNA polymerase similarity to repetitive regions found in many transcription II, as well as many cytoskeletal proteins and cytoplasmic factors.
    [Show full text]
  • The Yin–Yang of Kinase Activation and Unfolding Explains the Peculiarity Of
    RESEARCH ARTICLE The yin–yang of kinase activation and unfolding explains the peculiarity of Val600 in the activation segment of BRAF Christina Kiel1,2,3*, Hannah Benisty1,2,3, Veronica Llore´ ns-Rico1,2,3, Luis Serrano1,2,3,4* 1EMBL/CRG Systems Biology Research Unit, Centre for Genomic Regulation, Barcelona, Spain; 2Universitat Pompeu Fabra, Barcelona, Spain; 3Barcelona Institute of Science and Technology, Barcelona, Spain; 4Institucio´ Catalana de Recerca i Estudis Avanc¸ats, Barcelona, Spain Abstract Many driver mutations in cancer are specific in that they occur at significantly higher rates than – presumably – functionally alternative mutations. For example, V600E in the BRAF hydrophobic activation segment (AS) pocket accounts for >95% of all kinase mutations. While many hypotheses tried to explain such significant mutation patterns, conclusive explanations are lacking. Here, we use experimental and in silico structure-energy statistical analyses, to elucidate why the V600E mutation, but no other mutation at this, or any other positions in BRAF’s hydrophobic pocket, is predominant. We find that BRAF mutation frequencies depend on the equilibrium between the destabilization of the hydrophobic pocket, the overall folding energy, the activation of the kinase and the number of bases required to change the corresponding amino acid. Using a random forest classifier, we quantitatively dissected the parameters contributing to BRAF AS cancer frequencies. These findings can be applied to genome-wide association studies and prediction models. DOI: 10.7554/eLife.12814.001 *For correspondence: christina. [email protected] (CK); luis.serrano@crg. eu (LS) Introduction Competing interests: The In a time of personalized medicine and tumor sequencing, determining which missense mutations authors declare that no affect disease phenotype and exploring the role of cellular and environmental context are crucial.
    [Show full text]